Overview

A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia

Status:
Active, not recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
This research study is studying Ulocuplumab combined with ibrutinib as a possible treatment for symptomatic Waldenstrom's Macroglobulinemia (WM).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Bristol-Myers Squibb
Treatments:
Antibodies, Monoclonal